Biomarker directed treatment in metastatic colorectal cancer

Trial Profile

Biomarker directed treatment in metastatic colorectal cancer

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms AMGT-ERCC1
  • Most Recent Events

    • 23 Nov 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2015 Planned number of patients changed from 30 to 50, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top